Ibogaine Treatment Now Legal: Trump Executive Order and Texas Research Program Open New Doors for Addiction Recovery

Millions of Americans struggling with opioid and fentanyl addiction now have new hope following President Trump’s landmark Executive Order signed April 18, 2026, which fast-tracks ibogaine treatment through FDA pathways and expands Right to Try access. The Texas IMPACT program, backed by $50 million in state funding and led by UTHealth Houston and UTMB, is actively enrolling patients for research treatment at no cost to participants. Published studies show ibogaine can reduce opioid withdrawal symptoms by up to 95% and eliminate cravings in many patients after a single treatment session (PubMed 27089583). For those seeking enrollment in the Texas research program, contact UTHealth Houston at 713-500-3030 ext 3307 or email [email protected]. Here’s what the new executive order and Texas program mean for addiction treatment access.

Disclosure: We may earn a commission from links on this page at no extra cost to you. Affiliate relationships never influence our ratings. Full policy →

What is Ibogaine and Why is it Revolutionary for Addiction Treatment?

Ibogaine is a naturally occurring psychoactive compound found in the root bark of the African iboga plant (Tabernanthe iboga). Unlike traditional addiction treatments that require months or years of medication, ibogaine has shown the ability to interrupt addiction in a single treatment session lasting 24-36 hours.

The compound works through multiple mechanisms that researchers are still fully mapping. It appears to reset neural pathways associated with addiction, reduce physical withdrawal symptoms, and provide introspective experiences that help patients address the psychological roots of their substance use.

What makes ibogaine particularly promising for the opioid crisis is its effect on fentanyl addiction—one of the most difficult addictions to treat with conventional methods. Patients report dramatically reduced cravings and withdrawal symptoms following ibogaine treatment, effects that can last months or years.

Trump’s Executive Order: What Changed on April 18, 2026

President Donald Trump signed a landmark Executive Order on April 18, 2026 that fundamentally changes ibogaine’s status in the United States. This action represents the most significant shift in psychedelic medicine policy in American history.

Key Provisions of the Executive Order

FDA National Priority Vouchers: The order directs the FDA Commissioner to establish National Priority Vouchers for ibogaine research, fast-tracking clinical trials and regulatory review processes.

Right to Try Expansion: Perhaps most significantly, the order expands Right to Try laws to include patients with severe substance use disorders. This allows terminally ill patients or those with life-threatening addictions to access ibogaine treatment outside of clinical trials when standard treatments have failed.

$50 Million ARPA-H Funding: The order allocates $50 million from ARPA-H (Advanced Research Projects Agency for Health) specifically for ibogaine research, including safety protocols, dosing studies, and treatment outcome tracking.

Scheduling Review: The DEA has been directed to conduct a comprehensive scheduling review of ibogaine, potentially moving it from Schedule I to a schedule that allows medical use.

What This Means for Patients

The executive order creates two immediate pathways for Americans seeking ibogaine treatment:

1. Research Program Enrollment: Patients can now enroll in FDA-authorized research programs like Texas IMPACT
2. Right to Try Access: Patients who have failed conventional treatments may access ibogaine through Right to Try provisions with physician oversight

Texas IMPACT Program: America’s First State-Funded Ibogaine Research

Governor Greg Abbott signed Senate Bill 2308 in June 2025, establishing the Texas IMPACT (Integrated Mechanisms for Psychedelic Addiction and Consciousness Treatments) program with $50 million in funding from Texas Health and Human Services.

Lead Research Institutions

UTHealth Houston McGovern Medical School serves as the primary coordinating center for the research program. Their addiction medicine specialists are leading patient enrollment and treatment protocols.

University of Texas Medical Branch (UTMB) in Galveston provides the pharmacology and toxicology research infrastructure. Dr. Kathryn A. Cunningham, PhD, a leading researcher in addiction neuroscience, is among the key investigators.

Co-Principal Investigator: Dr. Charles Green, PhD, Professor at UTHealth Houston School of Behavioral Health Sciences and the Institute for Clinical Research and Learning Health Care at McGovern Medical School.

UT Austin and Baylor College of Medicine: Leading TBI Research

The original research collaboration began with UT Austin and Baylor College of Medicine in Houston, focusing specifically on traumatic brain injury (TBI) treatment for veterans:

The McGill Center for Psychedelic Research and Therapy at UT Austin Dell Medical School and Baylor College of Medicine are spearheading investigations into how ibogaine may benefit veterans and first responders suffering from traumatic brain injuries and associated PTSD.

This builds on a 2024 Stanford University study published in Nature Medicine showing ibogaine’s potential as a promising treatment for patients with traumatic brain injuries—a leading cause of PTSD in veterans.

Full Research Consortium Partners

The Texas IMPACT program brings together the state’s top medical and research institutions:

• UT Austin Dell Medical School + Baylor College of Medicine — Leading TBI research track for veterans and first responders
• UTHealth Houston + UTMB — Leading addiction treatment research track
• Texas Tech University Health Sciences Center — Rural treatment access and West Texas enrollment
• Texas A&M Health Science Center — Community health integration
• UNT Health Science Center — Primary care coordination
• JPS Health Network — Safety net hospital implementation in Dallas-Fort Worth

How to Enroll in the Texas IMPACT Program

Primary Contact:

• Name: Jeannette Sanchez
• Phone: 713-500-3030 ext 3307
• Email: [email protected]
• Institution: UTHealth Houston McGovern Medical School

Enrollment Requirements:

• Documented history of substance use disorder (opioid, fentanyl, alcohol, or other)
• Failed at least one conventional treatment approach
• No disqualifying cardiac conditions (EKG screening required)
• Texas residency preferred but not required for research enrollment
• Ability to complete follow-up assessments

What to Expect:

• Comprehensive medical and psychological screening
• Cardiac evaluation and EKG monitoring
• 24-48 hour supervised treatment session
• Integration support and follow-up care
• No cost to qualified participants (covered by program funding)

What Does the Research Show About Ibogaine’s Effectiveness?

While ibogaine has been used in international clinics for decades, American researchers now have the funding and authorization to conduct rigorous clinical trials. Here are the key published studies:

Published Research Findings

12-Month Follow-Up Study (PMID 28402682): An observational study measured addiction severity in 14 participants over 12 months following a single ibogaine treatment. Results showed significant reductions in opioid withdrawal scores acutely after treatment, with sustained reduced use in dependent individuals (PubMed 28402682).

Withdrawal and Craving Scores Study (PMID 29608409): Research tracking participants undergoing opioid detoxification with ibogaine found significant decreases in withdrawal symptoms. SOWS (Subjective Opioid Withdrawal Scale) scores decreased from 31.0 pretreatment to 14.0 at approximately 76.5 hours post-treatment (PubMed 29608409).

Large Case Series (PMID 10911935): An open label case series of 191 human volunteers seeking opioid detox found that ibogaine therapy administered in safe dose ranges diminishes opioid withdrawal symptoms and reduces drug cravings (PubMed 10911935).

Stanford TBI Study - Nature Medicine 2024 (PMID 38182784): The landmark Stanford study of 30 special operations veterans with TBI found magnesium-ibogaine therapy safely and effectively reduces PTSD, anxiety, and depression while improving cognitive function. Disability measures continued to improve and psychiatric symptom remission rates remained high after 1 month (PubMed 38182784).

How Ibogaine Compares to Conventional Treatments

Note: Ibogaine success rates are from observational studies; controlled trials through Texas IMPACT will provide more rigorous data.

Safety Considerations: What You Need to Know

Ibogaine is not without risks, which is precisely why medical supervision is essential. The Texas IMPACT program and FDA pathways ensure proper safety protocols.

Cardiac Risks

Ibogaine can prolong the QT interval in the heart, potentially causing dangerous arrhythmias in susceptible individuals. This is why:

• All program participants receive comprehensive cardiac screening
• EKG monitoring occurs before, during, and after treatment
• Patients with certain heart conditions are excluded
• Emergency cardiac equipment is available during treatment

Who Should NOT Receive Ibogaine

Current contraindications based on international treatment experience include:

• History of heart arrhythmias or prolonged QT interval
• Recent myocardial infarction (heart attack)
• Certain psychiatric conditions (schizophrenia, psychotic disorders)
• Severe liver or kidney disease
• Current use of certain medications that affect heart rhythm
• Pregnancy or breastfeeding

Why Medical Supervision Matters

Deaths associated with ibogaine have occurred almost exclusively in unsupervised settings or in clinics without proper cardiac monitoring. The Texas IMPACT program’s medical infrastructure addresses these concerns through:

• Hospital-based treatment settings
• 24-hour medical monitoring
• Immediate access to cardiac care
• Trained addiction medicine specialists
• Post-treatment integration support

The Path Forward: What’s Next for Ibogaine in America

President Trump’s Executive Order and the Texas IMPACT program represent the beginning of a new chapter in American addiction treatment. Here’s what to watch for in the coming months:

Immediate Developments (2026)

• Texas IMPACT enrollment expanding across the state
• Additional FDA-authorized research programs expected to launch
• Right to Try protocols being developed by addiction medicine specialists
• DEA scheduling review process beginning

Expected Progress (2027 and Beyond)

• Initial clinical trial results from Texas IMPACT
• Potential FDA breakthrough therapy designation
• More states expected to establish research programs following Texas model
• Private treatment centers may begin offering supervised ibogaine under Right to Try

How to Get Started

If you or a loved one is struggling with addiction and interested in ibogaine treatment through the Texas IMPACT program:

Step 1: Contact the Research Team

• Call 713-500-3030 ext 3307
• Email [email protected]
• Request enrollment information packet

Step 2: Gather Your Medical Records

• History of substance use treatment
• Cardiac health records
• Current medications list
• Mental health treatment history

Step 3: Complete Initial Screening

• Phone interview with research coordinator
• Review of medical history
• Discussion of program requirements and expectations

Step 4: Medical Evaluation

• Comprehensive physical examination
• EKG and cardiac screening
• Psychological assessment
• Determination of eligibility

External Resources

• UTHealth Houston IMPACT Program Official Announcement
• White House Executive Order on Psychedelics
• Stanford Nature Medicine Study on Ibogaine and TBI (2024)
• Texas Tribune: Texas Ibogaine Clinical Trials Coverage